17-Apr-2026
Globe Newswire (Mon, 13-Apr 8:32 AM ET)
Neuronetics Comments on Letter from Pointillist Family Office
Globe Newswire (Tue, 7-Apr 7:00 AM ET)
Neuronetics Announces Chief Financial Officer Transition
Globe Newswire (Mon, 6-Apr 4:30 PM ET)
PRNewswire (Mon, 6-Apr 4:05 PM ET)
Neuronetics Reports Fourth Quarter and Full Year 2025 Financial and Operating Results
Globe Newswire (Tue, 17-Mar 7:50 AM ET)
Neuronetics Appoints Dan Reuvers as President and Chief Executive Officer
Globe Newswire (Tue, 17-Mar 7:45 AM ET)
Neuronetics to Report Fourth Quarter 2025 Financial and Operating Results and Host Conference Call
Globe Newswire (Tue, 3-Mar 8:30 AM ET)
Diality Appoints Peter Donato as Chief Financial Officer
Business Wire (Tue, 24-Feb 7:05 AM ET)
Neuronetics' Clinic Revenue Jumps 37% and Positive Cash Flow Caps a Year of Rapid Expansion
Market Chameleon (Wed, 11-Feb 5:34 AM ET)
Globe Newswire (Tue, 10-Feb 4:34 PM ET)
Neuronetics Inc a commercial-stage medical technology company focused on designing, developing, and marketing products that improve the quality of life for patients who suffer from psychiatric disorders. Its first commercial product, the NeuroStar Advance Therapy System, is a non-invasive and non-systemic office-based treatment that uses transcranial magnetic stimulation, or TMS, to create a pulsed, MRI-strength magnetic field that induces electrical currents designed to stimulate specific areas of the brain associated with mood. The company designed the NeuroStar Advance Therapy as a non-invasive therapeutic alternative to treat patients who suffer from MDD and to address the existing treatment options. The company operates in two segments: medical devices and clinic services.
Neuronetics trades on the NASDAQ stock market under the symbol STIM.
As of April 17, 2026, STIM stock price climbed to $1.42 with 1,055,115 million shares trading.
STIM has a beta of 2.01, meaning it tends to be more sensitive to market movements. STIM has a correlation of 0.10 to the broad based SPY ETF.
STIM has a market cap of $98.37 million. This is considered a Micro Cap stock.
Last quarter Neuronetics reported $42 million in Revenue and -$.10 earnings per share. This beat revenue expectation by $933,500 and exceeded earnings estimates by $.01.
In the last 3 years, STIM traded as high as $5.92 and as low as $.52.
The top ETF exchange traded funds that STIM belongs to (by Net Assets): VTI, IWM, PSIL, VXF, IWO.
STIM has underperformed the market in the last year with a price return of -62.2% while the SPY ETF gained +36.3%. STIM has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -25.3% and -6.6%, respectively, while the SPY returned +2.9% and +8.3%, respectively.
STIM support price is $1.29 and resistance is $1.52 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that STIM shares will trade within this expected range on the day.
